Nuria Cayuela1, Esteban Jaramillo-Jiménez2, Estela Càmara3, Carles Majós1, Noemi Vidal1, Anna Lucas1, Miguel Gil-Gil1, Francesc Graus4, Jordi Bruna1,5, Marta Simó1,3. 1. Neuro-Oncology Unit, Bellvitge University Hospital, Bellvitge Biomedical Research Institute-Catalan Institute of Oncology (IDIBELL) (Oncobell program), Barcelona, Spain. 2. Neuro-Oncology Unit, Colombian Neurological Institute, CES University, Medellín, Colombia. 3. Cognition and Brain Plasticity Group, IDIBELL, Barcelona, Spain. 4. Department of Neurology, August Pi i Sunyer Biomedical Research Institute (IDIBAPS) Hospital Clínic, Barcelona, Spain. 5. Institute of Neurosciences, Department of Cell Biology, Physiology, and Immunology, Autonomous University of Barcelona, Biomedical Research Networking Center on Neurodegenerative Diseases (CIBERNED), Bellaterra, Spain.
Abstract
BACKGROUND: We identify cognitive impairment and MRI structural brain changes in long-term oligodendroglial tumor survivors treated with radiation therapy (RT) alone (21%) or with chemotherapy (CT) (79%). METHODS: Oligodendroglial tumor patients (based on the World Health Organization [WHO] 2007 classification) who completed RT ± CT at least 2 years before the study initiation, were classified into 3 groups according to the time treatment was completed: Group 1 = 2-5 years (n = 22), Group 2 = 6-10 years (n = 13), and Group 3 >10 years (n = 13). All patients had a cross-sectional neuropsychological evaluation (n = 48) and a longitudinal volumetric analysis (gray matter [GM; n = 34]) between postsurgical and last follow-up MRI. White matter (WM) changes on MRI were assessed using a qualitative scale. RESULTS: There were no differences regarding tumor or treatment-related characteristics between groups. Six of 22 patients (27.3%) in Group 1; 5/13 (38.5%) in Group 2; and 9/13 (69.2%) in Group 3 had cognitive impairment that was considered severe in 3/22 patients (13.6%) in Group 1; 4/13 (30.8%) in Group 2; and 6/13 (46.2%) in Group 3. Patients in Groups 2 and 3 showed significant GM atrophy and more leukoencephalopathy than Group 1. Cognitive deficits were associated with brain atrophy and WM changes. CONCLUSIONS: Long-term oligodendroglial tumor survivors who underwent standard RT ± CT treatment, mainly >5 years of its completion, present cognitive impairment, especially on memory and executive functions, associated with late GM and WM damage, thus highlighting the need of developing future strategies in patients with oligodendroglial tumor and long expected survival.
BACKGROUND: We identify cognitive impairment and MRI structural brain changes in long-term oligodendroglial tumor survivors treated with radiation therapy (RT) alone (21%) or with chemotherapy (CT) (79%). METHODS:Oligodendroglial tumorpatients (based on the World Health Organization [WHO] 2007 classification) who completed RT ± CT at least 2 years before the study initiation, were classified into 3 groups according to the time treatment was completed: Group 1 = 2-5 years (n = 22), Group 2 = 6-10 years (n = 13), and Group 3 >10 years (n = 13). All patients had a cross-sectional neuropsychological evaluation (n = 48) and a longitudinal volumetric analysis (gray matter [GM; n = 34]) between postsurgical and last follow-up MRI. White matter (WM) changes on MRI were assessed using a qualitative scale. RESULTS: There were no differences regarding tumor or treatment-related characteristics between groups. Six of 22 patients (27.3%) in Group 1; 5/13 (38.5%) in Group 2; and 9/13 (69.2%) in Group 3 had cognitive impairment that was considered severe in 3/22 patients (13.6%) in Group 1; 4/13 (30.8%) in Group 2; and 6/13 (46.2%) in Group 3. Patients in Groups 2 and 3 showed significant GM atrophy and more leukoencephalopathy than Group 1. Cognitive deficits were associated with brain atrophy and WM changes. CONCLUSIONS: Long-term oligodendroglial tumor survivors who underwent standard RT ± CT treatment, mainly >5 years of its completion, present cognitive impairment, especially on memory and executive functions, associated with late GM and WM damage, thus highlighting the need of developing future strategies in patients with oligodendroglial tumor and long expected survival.
Authors: N W Scott; P M Fayers; N K Aaronson; A Bottomley; A de Graeff; M Groenvold; M Koller; M A Petersen; M A G Sprangers Journal: Qual Life Res Date: 2006-11-16 Impact factor: 4.147
Authors: Nadia N Laack; Paul D Brown; Robert J Ivnik; Alfred F Furth; Karla V Ballman; Julie E Hammack; Robert M Arusell; Edward G Shaw; Jan C Buckner Journal: Int J Radiat Oncol Biol Phys Date: 2005-06-20 Impact factor: 7.038
Authors: Jan C Buckner; Edward G Shaw; Stephanie L Pugh; Arnab Chakravarti; Mark R Gilbert; Geoffrey R Barger; Stephen Coons; Peter Ricci; Dennis Bullard; Paul D Brown; Keith Stelzer; David Brachman; John H Suh; Christopher J Schultz; Jean-Paul Bahary; Barbara J Fisher; Harold Kim; Albert D Murtha; Erica H Bell; Minhee Won; Minesh P Mehta; Walter J Curran Journal: N Engl J Med Date: 2016-04-07 Impact factor: 91.245
Authors: I J Torres; A J Mundt; P J Sweeney; S Llanes-Macy; L Dunaway; M Castillo; R L Macdonald Journal: Neurology Date: 2003-04-08 Impact factor: 9.910
Authors: Christopher H Chapman; Vijaya Nagesh; Pia C Sundgren; Henry Buchtel; Thomas L Chenevert; Larry Junck; Theodore S Lawrence; Christina I Tsien; Yue Cao Journal: Int J Radiat Oncol Biol Phys Date: 2011-05-11 Impact factor: 7.038
Authors: Morgan L Prust; Kourosh Jafari-Khouzani; Jayashree Kalpathy-Cramer; Pavlina Polaskova; Tracy T Batchelor; Elizabeth R Gerstner; Jorg Dietrich Journal: Neuro Oncol Date: 2018-01-22 Impact factor: 12.300
Authors: Linda Douw; Martin Klein; Selene Saa Fagel; Josje van den Heuvel; Martin Jb Taphoorn; Neil K Aaronson; Tjeerd J Postma; W Peter Vandertop; Jacob J Mooij; Rudolf H Boerman; Guus N Beute; Jasper D Sluimer; Ben J Slotman; Jaap C Reijneveld; Jan J Heimans Journal: Lancet Neurol Date: 2009-08-07 Impact factor: 44.182
Authors: Tracy L Luks; Javier E Villanueva-Meyer; Christina Weyer-Jamora; Karin Gehring; Angela Jakary; Shawn L Hervey-Jumper; Steve E Braunstein; Paige M Bracci; Melissa S Brie; Ellen M Smith; Susan M Chang; Jennie W Taylor Journal: Front Neurol Date: 2022-01-28 Impact factor: 4.003
Authors: A Gommlich; J Petr; F Raschke; A Seidlitz; C Jentsch; I Platzek; J van den Hoff; J Kotzerke; B Beuthien-Baumann; M Baumann; M Krause; E G C Troost Journal: MAGMA Date: 2021-03-31 Impact factor: 2.310
Authors: F Raschke; K Witzmann; A Seidlitz; T Wesemann; C Jentsch; I Platzek; J van den Hoff; J Kotzerke; B Beuthien-Baumann; M Baumann; J Linn; M Krause; E G C Troost Journal: Clin Transl Radiat Oncol Date: 2022-07-20